US30205M2008 - Common Stock
EXICURE INC
NASDAQ:XCUR (4/19/2024, 7:24:58 PM)
0.561
-0.02 (-3.08%)
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 7 full-time employees. The company went IPO on 2018-05-09. The firm is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. The company is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The firm focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.
EXICURE INC
2430 N. Halsted St.
Chicago ILLINOIS 60614
P: 18476731700
CEO: David A. Giljohann
Employees: 7
Website: https://www.exicuretx.com/
It's time to start Tuesday with a breakdown of the biggest pre-market stock movers that investors will want to keep an eye on today!
We're starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning!
Here you can normally see the latest stock twits on XCUR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: